Methodological issues in assessing health-related quality of life of colorectal cancer patients in randomised controlled trials

被引:63
作者
Efficace, F
Bottomley, A
Vanvoorden, V
Blazeby, JM
机构
[1] Eortc Data Ctr, Qual Life Unit, European Org Res Treatment Canc, B-1200 Brussels, Belgium
[2] Univ Bristol, Dept Surg, Bristol, Avon, England
[3] Univ Bristol, Dept Social Med, Bristol, Avon, England
关键词
colorectal cancer; quality of life; randomised controlled trial; systematic review;
D O I
10.1016/j.ejca.2003.10.012
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Although health-related quality of life (HRQOL) is increasingly reported as an important endpoint in cancer clinical trials, questions still remain about the quality of its reporting. The aim of this study was to evaluate the level of reporting of HRQOL in randomised controlled trials (RCTs) of colorectal cancer (CRC). A systematic literature search from 1980 to March 2003 was undertaken on a number of databases. Identified eligible studies were selected and then evaluated on a broad set of HRQOL predetermined criteria by four reviewers. Thirty-one randomised controlled trials involving 9683 colorectal cancer patients were identified. Nearly all studies dealt with metastatic patients and principally compared different chemotherapy regimens. The HRQOL tool most often used was the European Organisation for Research and Treatment of Cancer, Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30), which was used in 48% of the studies. Some methodological limitations were identified: 39% of the RCTs did not report HRQOL compliance at baseline and 52% did not give details on missing data. A rationale for using a specific HRQOL measure was given in only 10% of the studies. Whilst HRQOL assessment is a potential valuable source of information in understanding the impact of colorectal cancer, a number of methodological shortcomings have to be further addressed in future studies. (C) 2003 Elsevier Ltd. All rights reserved.
引用
收藏
页码:187 / 197
页数:11
相关论文
共 68 条
[1]   Randomized trial of regional plus systemic fluorinated pyrimidine compared with systemic fluorinated pyrimidine in treatment of colorectal liver metastases [J].
Allen-Mersh, TG ;
Glover, C ;
Fordy, C ;
Mathur, P ;
Quinn, H .
EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 2000, 26 (05) :468-473
[2]   QUALITY-OF-LIFE AND SURVIVAL WITH CONTINUOUS HEPATIC-ARTERY FLOXURIDINE INFUSION FOR COLORECTAL LIVER METASTASES [J].
ALLENMERSH, TG ;
EARLAM, S ;
FORDY, C ;
ABRAMS, K ;
HOUGHTON, J .
LANCET, 1994, 344 (8932) :1255-1260
[3]  
[Anonymous], 2002, GUIDELINES ASSESSING
[4]  
Bernhard J, 1998, STAT MED, V17, P517, DOI 10.1002/(SICI)1097-0258(19980315/15)17:5/7<517::AID-SIM799>3.0.CO
[5]  
2-S
[6]   A double-blind placebo-controlled randomized phase III trial of 5-fluorouracil and leucovorin, plus or minus trimetrexate, in previously untreated patients with advanced colorectal cancer [J].
Blanke, CD ;
Shultz, J ;
Cox, J ;
Modiano, M ;
Isaacs, R ;
Kasimis, B ;
Schilsky, R ;
Fleagle, J ;
Moore, M ;
Kemeny, N ;
Carlin, D ;
Hammershaimb, L ;
Haller, D .
ANNALS OF ONCOLOGY, 2002, 13 (01) :87-91
[7]   Health-related quality of life in non-small-cell lung cancer: Methodologic issues in randomized controlled trials [J].
Bottomley, A ;
Efficace, F ;
Thomas, R ;
Vanvoorden, V ;
Ahmedzai, SH .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (15) :2982-2992
[8]   Quality of life in patients undergoing systemic therapy for advanced breast cancer [J].
Bottomley, A ;
Therasse, P .
LANCET ONCOLOGY, 2002, 3 (10) :620-628
[9]   Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer [J].
Carmichael, J ;
Popiela, T ;
Radstone, D ;
Falk, S ;
Borner, M ;
Oza, A ;
Skovsgaard, T ;
Munier, S ;
Martin, C .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (17) :3617-3627
[10]   A RANDOMIZED STUDY OF BOLUS FLUOROURACIL PLUS FOLINIC ACID VERSUS 21-DAY FLUOROURACIL INFUSION ALONE OR IN ASSOCIATION WITH CYCLOPHOSPHAMIDE AND MITOMYCIN-C IN ADVANCED COLORECTAL-CARCINOMA [J].
CAUDRY, M ;
BONNEL, C ;
FLOQUET, A ;
MARSAULT, C ;
QUETIN, P ;
PUJOL, J ;
MATON, O ;
DUJOLS, JP ;
CAUDRY, Y ;
SKAWINSKI, P ;
CARENCO, J ;
MOKHTARI, F ;
CELERIER, D ;
QUINTON, A ;
DEMEAUX, H ;
MAIRE, JP .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1995, 18 (02) :118-125